MX2010003849A - Antagonistas de cgrp. - Google Patents

Antagonistas de cgrp.

Info

Publication number
MX2010003849A
MX2010003849A MX2010003849A MX2010003849A MX2010003849A MX 2010003849 A MX2010003849 A MX 2010003849A MX 2010003849 A MX2010003849 A MX 2010003849A MX 2010003849 A MX2010003849 A MX 2010003849A MX 2010003849 A MX2010003849 A MX 2010003849A
Authority
MX
Mexico
Prior art keywords
sup
salts
cgrp antagonists
hydrates
tautomers
Prior art date
Application number
MX2010003849A
Other languages
English (en)
Inventor
Klaus Rudolf
Stephan Georg Mueller
Dirk Stenkamp
Henri Doods
Gerhard Schaenzle
Dirk Gottschling
Annekatrin Heimann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2010003849A publication Critical patent/MX2010003849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Son objeto de la presente invenci?n nuevos antagonistas de CGRP de la f?rmula general (I) (Ver f?rmula I) en la que U, V, X, Y, R1, R2 y R3 est?n definidos como se menciona en lo que sigue, sus taut?meros, sus is?meros, sus diastereois?meros, sus enanti?meros, sus hidratos, sus mezclas y sus sales, as? como los hidratos de las sales, en especial sus sales fisiol?gicamente compatibles con ?cidos o bases inorg?nicos u org?nicos, medicamentos que contienen a estos compuestos, su uso y procedimientos para su preparaci?n.
MX2010003849A 2007-10-18 2008-10-16 Antagonistas de cgrp. MX2010003849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118811 2007-10-18
PCT/EP2008/063967 WO2009050234A1 (de) 2007-10-18 2008-10-16 Cgrp-antagonisten

Publications (1)

Publication Number Publication Date
MX2010003849A true MX2010003849A (es) 2010-04-27

Family

ID=39047647

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003849A MX2010003849A (es) 2007-10-18 2008-10-16 Antagonistas de cgrp.

Country Status (17)

Country Link
US (1) US8450327B2 (es)
EP (2) EP2205599B1 (es)
JP (1) JP5366960B2 (es)
KR (1) KR20100091972A (es)
CN (1) CN101827845A (es)
AU (1) AU2008313733A1 (es)
BR (1) BRPI0817835A2 (es)
CA (1) CA2702503A1 (es)
CO (1) CO6270226A2 (es)
EA (1) EA201000612A1 (es)
EC (1) ECSP10010105A (es)
IL (1) IL204928A0 (es)
MA (1) MA31782B1 (es)
MX (1) MX2010003849A (es)
NZ (1) NZ585347A (es)
TN (1) TN2010000173A1 (es)
WO (1) WO2009050234A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
EP2065381A1 (de) * 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
EP2251338A3 (de) * 2007-11-22 2011-06-08 Boehringer Ingelheim International GmbH Organische Verbindungen
US8653269B2 (en) 2010-03-12 2014-02-18 Nippon Soda Co., Ltd. Process for preparation of t-butoxycarbonylamine compounds
WO2015119848A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
EP3464272B1 (en) 2016-06-07 2021-12-08 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
AU2018239542C1 (en) 2017-03-23 2021-02-11 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as SHP2 inhibitors
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20003672A3 (cs) 1998-04-10 2001-08-15 G. D. Searle & Co. Heterocyklické glycyl-beta-alaninové deriváty jako agonisté vitronektinu
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1322628A2 (en) 2000-09-14 2003-07-02 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
KR20120004541A (ko) 2002-06-05 2012-01-12 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP2007513058A (ja) 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7659300B2 (en) 2004-09-08 2010-02-09 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
WO2006031513A2 (en) * 2004-09-09 2006-03-23 Merck & Co., Inc. Aryl spirolactam cgrp receptor antagonists
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP5426878B2 (ja) 2005-05-24 2014-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ−結合カセットトランスポーターのモジュレーター
MX2007015705A (es) 2005-06-29 2008-02-15 Palau Pharma Sa Derivados biciclicos como inhibidores de la cinasa p38.
DE102005050892A1 (de) 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GEP20115140B (en) 2006-05-09 2011-01-10 Merck Sharp And Dome Corp Substituted spirocyclic cgrp receptor antagonists
WO2008070014A2 (en) 2006-12-04 2008-06-12 Neurogen Corporation Biaryl ketone-substituted piperidines
WO2009034029A2 (de) 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
EP2065381A1 (de) * 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
KR20100091972A (ko) 2007-10-18 2010-08-19 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ 길항제
EP2062889A1 (de) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
JP2011504481A (ja) * 2007-11-22 2011-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物
EP2251338A3 (de) * 2007-11-22 2011-06-08 Boehringer Ingelheim International GmbH Organische Verbindungen

Also Published As

Publication number Publication date
EP2386558B1 (de) 2014-10-01
EP2205599A1 (de) 2010-07-14
ECSP10010105A (es) 2010-06-29
US20110172218A1 (en) 2011-07-14
JP5366960B2 (ja) 2013-12-11
IL204928A0 (en) 2010-11-30
BRPI0817835A2 (pt) 2015-03-31
KR20100091972A (ko) 2010-08-19
CN101827845A (zh) 2010-09-08
MA31782B1 (fr) 2010-10-01
CA2702503A1 (en) 2009-04-23
WO2009050234A1 (de) 2009-04-23
CO6270226A2 (es) 2011-04-20
NZ585347A (en) 2011-09-30
EP2205599B1 (de) 2012-06-06
US8450327B2 (en) 2013-05-28
EA201000612A1 (ru) 2010-10-29
AU2008313733A1 (en) 2009-04-23
EP2386558A1 (de) 2011-11-16
JP2011500637A (ja) 2011-01-06
TN2010000173A1 (fr) 2011-11-11

Similar Documents

Publication Publication Date Title
WO2009065919A3 (de) Organische verbindungen
WO2009065920A3 (de) Verbindungen
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
MX2010003849A (es) Antagonistas de cgrp.
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
WO2009065922A3 (de) Organische verbindungen
TW200738692A (en) New substituted glycinamides, process for their manufacture and use thereof as medicaments
WO2007036532A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
RS20050329A (en) Selected cgrp antagonists,method for production and use thereof as medicament
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
TW200745066A (en) Novel PTP1B inhibitors
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200602033A (en) New carboxylic acid amides, the preparation thereof and their use as medicaments
MY153941A (en) Compounds as bradykinin b1 antagonists
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
MY148769A (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
WO2009065921A3 (de) Organischeverbindungen
TW200740798A (en) Substituted amides, process for their manufacture and use thereof as medicaments
WO2008135525A3 (en) Substituted azetidines, manufacturing and use thereof as medicaments
WO2006100026A8 (de) 2-oxo-1,2,4,5-tetrahydro-1,3-benzdiazepin-3-yl-piperidine als cgrp-antagonisten
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
WO2007036533A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration